Hubungan Antara Kadar CA-125 dengan Jenis Histopatologi Tumor Epitel Ganas Ovarium di Rumah Sakit H.Adam Malik Medan pada tahun 2013 – 2015

49

DAFTAR PUSTAKA

1. Birrer M. Ovarian Cancer: Targeting the Untargetable. American Society
of Clinical Oncology Educational Book. 2014;34:13-15.
2. Sahil F.M. Penatalaksanaan Kanker Ovarium pada Wanita Usia Mudan
dengan Mempertahankan Fungsi Reproduksi. [Internet]. 1st ed. Medan:
Repository USU; 2007 [cited 17 April 2016]. Available from:
http://www.repository.usu.ac.id
3. Badan Registrasi Kanker. Kanker di Indonesia tahun 2006 Data
Histopatologik. Jakarta: Yayasan Kanker Indonesia; 2006.
4. Coleman R.L., Gerhenson D.M. Neoplastic Disease of The Ovary, in: Katz
V.L., Lentz G.M., Lobo R.A., Gerhenson D.M. Comprehensive
Gynecology. 5th ed. Philadelphia: Mosby Elsevier. 2007.
5. World Health Organization. WHO Classification of Tumours of Female
Reproductive Organ. 4th ed. World Health Organization; 2014.
6. Berek J.S., Natarajan S. Ovarian and Fallopian Tube Cancer, in: Berek $
Novak’s Gynecology. 14th ed. California: Lippincot William & Wilkins.
2007. p: 1457-1531.
7. Copeland L.J. Epithelial Ovarian Cancer, in : Clinical Gynecologic

Oncology. 7th ed. Mosby Elsevier inc. 2007. p: 317-371.
8. Fujin C., Zhongli C., Minshan C., Yingbo C., Zhongping C., Nianji C., et
al.,editors. Buku Ajar Onkologi Klinis. Edisi 2. Jakarta: Badan Penerbit
FK UI; 2013.
9. Gupta, D. And Lis, C.G. Role of CA-125 in predicting ovarian cancer in
general population. Past practice & Research Clinical Obstetrics and
Gynaecology 26, 2012: 243-256.
10. Sturgeon C, Diamandis E. Use of tumor markers in testicular, prostate,
colorectal, breast, and ovarian cancer. The American Association for
clinical biochemistry. 2009. Hal.51-60
11. Prawirohardjo S., editors. Ilmu Kandungan: Kanker Ganas Alat Genital.
Edisi

3.

Jakarta:

Tridasa

Printer;

2011.

p.

307-314

48
52

Universitas Sumatera Utara

49

12. Eroschenko VP. Atlas Histologi diFiore: Sistem Reproduksi Wanita. Edisi
11. Jakarta: Penerbit Buku Kedokteran EGC; 2008. p.455-462.
13. Widayati

P.,

Ariyanto

A.,

Lestari

W.

Produksi

KIT

Immunoradiometricassay (IRMA) CA-125 untuk Deteksi Dini Kanker
Ovarium. April 2011.
14. Aziz M.F., et al. Buku Acuan Nasional Onkologi Ginecologi. Edisi 6.
Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo FKUI; 2006.
p.468-527.
15. Bintang A.P., Maria. Profil Penderita Tumor Ganas Ovarium di Rumah
Sakit H.Adam Malik Medan pada tahun 2012.[internet].1st ed.Medan:
Repository

USU;

2014

[cited

17

April

2016]Available

from:

http://www.repository.usu.ac.id
16. Robbins., Kumar., Abbas., Aster.. Buku Ajar Patologi. Edisi 9. Jakarta:
Elsevier; 2015.
17. Nucci M.R., Oliva E., editors. Gynecologic Pathology: Surface Epithelial
Stromal Tumors of The Ovary. Boston: Elsevier churcchill livingstone;

2009.
18. DoveMed [Internet]. DoveMed. 2015 [cited 17 April 2016]. Available
from: http://www.dovemed.com
19. Agarwal, P. and Kehoe, S. Serum tumour marker in gynaecological
cancers. Maturitas 67, 2010: 46-53.
20. Rancourt, C., Matte, I., Lane, D., Piche, A. The role of MUC16 mucin
(CA125) in the pathogenesis of ovarian cancer. Ovarian Cancer- Basic
Science Perspective, available from : www.intechopen.com. Diunduh pada
2 Februari 2014.
21. Scholler, N. and Urban, N. 2007. CA125 in ovarian cancer. Biomark Med,
2007: December; 1(4): 513-523.
22. Gentry-Maharaj, A. and Menon, U. Screening for ovarian cancer in
general population. Best Practice & Research Clinical Obstetrics and
Gynaecology 26, 2012: 243-256.

52

Universitas Sumatera Utara

50

49

23. Das, P.M. and Bast, R.C. Early Detection of ovarian cancer. Biomark Med,
2008: June; 2(3): 291-303.
24. Foundation for Women’s Cancer [internet]. Ovarian Cancer. Foundation
for Women’s Cancer. 2016. [cited 17 April 2016]. Available from:
www.foundationforwomenscancer.org
25. E L Moss, J Hollingworth, T M Reynolds . The role of CA125 in clinical
practice,

Available

from

URL

:

jcp.bmj.com

Published

by

:

group.bmj.com
26. Ferdyansyah T., Sofian A., Fatmawati. Hubungan Tumor Marker CA-125
dengan Sifat dan Tipe Sel Tumor Ovarium di RSUD Arifin Achmad
Pekanbaru. Pekanbaru; April 2014.
27. C Ben, T Drik, B Tom, T Antonia, H Caroline, D Ekaterini, J Davor, N
Patrick, et al. Discrimination between benign and malignant by specialist
ultrasound examination versus serum CA-125.Journal National cancer
institute. 2007
28. FIGO, Annual report on the Result of Treatment I Gynecological, J Epid
Biostat, 1998.
29. Regarding Ovarian Cancer, advanced obgyn associated obstetric
gynecology & infertilty. Available from URL : http://www.advanced
obgynassociates.com/ovarian-cancer.htm
30. Women Should be offered a blood test for ovarian cancer, NICE

Guidance. United Kingdom’s National Institute for health & Clinical
Excellence 2011.
31. Barliana., Faroek Hoesin., Dyah Fauziah. Ekspresi Protein HER-2/neu
pada Berbagai Tipe Karsinoma Ovarium. Januari 2014.
32. Andi F.F., Zulkifly A., Syamsiar S.R. Faktor Risiko Kanker Ovarium di
RSUP Wahidin Sudirohusodo Makassar. 2014.
33. Badan Penelitian dan Pengembangan Indonesia. Prevalensi Tumor dan
Beberapa Faktor yang Mempengaruhinya di Indonesia. Oktober 2011.

52

Universitas Sumatera Utara

49
51

34. Pemaron I.B.U. Modifikasi Indeks Risiko Keganasan Sebagai Modalitas
Diagnostik Preoperatif Untuk Memprediksi Keganasan Tumor Ovarium :
Suatu Uji Diagnostik. 2013.

52

Universitas Sumatera Utara